Abbvie Inc Stock Price, News & Analysis

AbbVie (ABBV) reported full-year 2024 financial results with net revenues of $56.334 billion, up 3.7% on a reported basis. The company's diluted EPS was $2.39 (GAAP), down 12.1%, while adjusted EPS was $10.12, down 8.9%.

Key portfolio performance includes: Immunology revenues of $26.682 billion (+2.1%), with Skyrizi reaching $11.718 billion and Rinvoq $5.971 billion; Oncology revenues of $6.555 billion (+10.8%); Neuroscience portfolio at $8.999 billion (+16.6%); and Aesthetics portfolio at $5.176 billion (-2.2%).

Looking ahead, AbbVie provided 2025 adjusted EPS guidance of $12.12-$12.32 and raised its 2027 combined sales outlook for Skyrizi and Rinvoq to over $31 billion. The company expects high single-digit compound annual revenue growth through 2029.

Allergan Aesthetics, an AbbVie Company, has launched the new AA Signature program at IMCAS World Congress 2025, introducing an innovative approach to aesthetic treatment planning. The program focuses on delivering personalized, patient-centric solutions through their advanced product portfolio.

Research shows that 8 in 10 patients proceed with treatment following holistic consultation, and clinics using multi-area treatment plans experience a 68% higher retention rate. The program addresses three key patient needs: Lift (structure and skin firmness), Definition (enhanced facial angles), and Skin quality (smoothness and hydration).

The initiative includes advanced training and education modules for healthcare providers (HCPs), supporting them with combination product use and comprehensive educational programs. The program will be gradually introduced worldwide to reflect new trends, products, and indications.

Allergan Aesthetics, an AbbVie company, announces the launch of its new AA Signature Program at IMCAS World Congress 2025 in Paris. The program offers a personalized approach to aesthetic treatment planning, focusing on lift, definition, and skin quality improvements.

Research indicates that 80% of patients proceed with treatments following holistic consultations, and clinics using multi-area treatment plans see a 68% higher retention rate. The congress will feature an AMI symposium with live injection demonstrations, expert presentations, and an interactive exhibition booth.

The event includes a Medical Symposium on 'Mastering the Lower Face and Neck' and Meet the Experts sessions featuring renowned professionals like Dr. Jean Carruthers, who pioneered the cosmetic use of neuromodulators. The Allergan Aesthetics booth (E130, Level 1) will serve as a discovery hub for the new program and product portfolio.

AbbVie (NYSE: ABBV) has completed its acquisition of Nimble Therapeutics, strengthening its pipeline and R&D capabilities in immunology. The acquisition brings two key assets: a potential novel oral peptide IL23R inhibitor in preclinical development for psoriasis treatment, and Nimble's proprietary peptide synthesis, screening, and optimization platform.

The platform utilizes proprietary technology to accelerate the discovery and optimization of oral peptide candidates across various targets. Following the completion, Nimble has been integrated into AbbVie, with its team joining AbbVie's efforts to advance autoimmune disease treatments.

AbbVie (NYSE: ABBV) and Neomorph have announced a collaboration and option-to-license agreement to develop molecular glue degraders for oncology and immunology targets. The partnership combines AbbVie's expertise in drug development with Neomorph's molecular glue discovery platform.

Molecular glue degraders represent a novel class of small molecules designed to selectively target and trigger degradation of proteins involved in cancer growth and immune system dysregulation, including previously 'undruggable' proteins.

Under the agreement terms, Neomorph will receive an upfront payment and is eligible for up to $1.64 billion in option fees and milestones, plus tiered royalties on net sales.

Simcere Zaiming and AbbVie (ABBV) have announced a partnership to develop SIM0500, a novel trispecific antibody candidate for multiple myeloma treatment. The drug, currently in Phase 1 clinical trials in China and the U.S., targets GPRC5D, BCMA, and CD3 proteins.

The agreement includes an upfront payment from AbbVie to Simcere Zaiming, with potential milestone payments reaching up to $1.055 billion, plus tiered royalties on net sales outside Greater China. AbbVie will receive tiered royalties on sales within Greater China.

SIM0500, developed using Simcere Zaiming's T-cell engager polyspecific antibody technology platform, has demonstrated strong T cell cytotoxicity against multiple myeloma cells through various antitumor effects.

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022. The expanded agreement gives AbbVie access to AbCellera's TCE platform for developing therapeutic antibodies targeting tumors.

Under the agreement terms, AbCellera will lead discovery activities while AbbVie retains development and commercialization rights for resulting therapeutic antibodies. AbCellera will receive upfront and research payments, plus potential downstream milestone payments and tiered royalties on net sales.

AbbVie (NYSE: ABBV) and Simcere Zaiming have announced a partnership to develop SIM0500, a novel trispecific antibody for multiple myeloma. The drug candidate, currently in Phase 1 clinical trials in China and the U.S., targets GPRC5D, BCMA, and CD3 using Simcere's T-cell engager polyspecific antibody technology platform.

The agreement includes an upfront payment from AbbVie to Simcere Zaiming, with potential option fees and milestone payments reaching up to $1.055 billion, plus tiered royalties on net sales outside Greater China. AbbVie will receive tiered royalties on sales within the Greater China territory. SIM0500 has demonstrated strong T cell cytotoxicity against multiple myeloma cells through various antitumor effects.

AbbVie (ABBV) and REGENXBIO (RGNX) have announced key updates for their ABBV-RGX-314 clinical program. The companies expect pivotal data on the safety and efficacy of subretinal delivery for wet age-related macular degeneration (wet AMD) patients in 2026 through the ATMOSPHERE® and ASCENT™ trials.

Additionally, both companies will plan a Phase 3 clinical program for diabetic retinopathy (DR) treatment using suprachoroidal delivery via the SCS Microinjector®. This gene therapy aims to address the treatment burden of chronic, frequent dosing in retinal diseases, which are among the leading causes of blindness. ABBV-RGX-314 is being developed as the first potential one-time gene therapy for both wet AMD and DR patients.